For its first fiscal quarter (ending March 31), Bristol-Myers Squibb Co (NYSE: BMY) has reported E.P.S. of $-5.89 compared to $1.08 a year ago. E.P.S. were $-3.09 for the latest four quarters through March 31 versus $3.46 for the same period a year ago.
Recent Price Action
On 4/25/24, Bristol-Myers Squibb Co (NYSE: BMY) stock suffered a large decline of -8.5%, closing at $44.70. Moreover, exceptionally high trading volume at 284% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -6.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, BMY is expected to continue to be a major Value Builder.
Bristol-Myers Squibb has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Bristol-Myers Squibb has a neutral Appreciation Score of 57 but a poor Power Rating of 17, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment